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Abstract
Peptide synthesis and modification is a versatile chemical biology strategy to construct probes and
sensors of a variety of types of biological activity, including protein/protein interactions, protein
localization, and proteolysis. In my thesis work, I have made probes for three distinct biological
applications. To do so, I have used a combination of solid phase peptide synthesis (SPPS), native
chemical ligation (NCL), protein expression, and S-alkylation to construct probes with desired functional
groups, while minimizing the perturbation to the native structure. In the first project, I constructed photocrosslinking probes to study the difference in protein-protein interactions of N-terminal acetylated (N-ac)
histone H4 peptide versus non-acetylated histone H4 peptide. One protein was identified by Western blot
with binding preference to N-Ace histone H4 peptide. In the second separate project, I constructed probes
to study the toxicity mechanism of proline/arginine dipeptide PRx from amyotrophic lateral sclerosis
(ALS) associated gene C9ORF72. The preliminary result suggested the PRx peptide toxicity on
proteasome depends on the length of the (PR)x peptide. In the third project, I synthesized fluorescence
sensors to study the positional effects of thioamide on the proteolysis process of chymotrypsin. From
hydrolysis studies, my coworkers and I determined that thioamide incorporation at the P1 or P2 positions
can greatly inhibit chymotrypsin proteolysis.
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Chapter 1
Development of Protein Binding Probes
Introduction
Peptide synthesis and protein modification are powerful synthetic strategies that
combine the flexibility of organic synthesis and the convenience of recombinant
protein expression. By using a combination of synthetic approaches, functional
groups can be added to the peptides or proteins of interest, such as fluorophores,
unnatural amino acids, photo-crosslinkers, and purification tags. Similarly,
synthetic approaches can be used to modify the backbone of the peptide. Modified
peptides have wide applications in drug design, live imaging, and other biological
studies. For example, Nafarelin® is an analog of the naturally occurring
gonadotropin-releasing hormone (GnRH) with modification at position 6 (shown in
red) in Figure 1A.1 This modification significantly extends the half-life from 2-4
minutes2 to 2.6-4 hours.1 Another example from Nguyen and coworkers3 showed
a caged TEV (Tobacco Etch Virus) protease can be activated by release of the
caging group under light irradiation, allowing manipulation of protease activity by
light, as shown in Figure 1B.

Figure 1. Examples of Modified Peptide and Proteins. (A): a GnRH analog
Nafarelin, marketed as Synarel® by Pfizer.1 (B): The TEV protease is inactivated
with a caged cysteine.3
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I hope to use peptide synthesis and modification methods to construct probes
to solve biological questions. Based on the probes applications, this study is
divided into projects 1 and 2. Project 1 involves synthesis of photo-crosslinking
probes and then studies the functions of histone H4 N-terminal acetylation (N-ac).
Project 2 involves synthesis of a photo-crosslinking probe and a fluorescence
probe, followed by study on the toxicity mechanism of proline-arginine tandem
repeat peptides PRx on amyotrophic lateral sclerosis (ALS). Since project 1 and 2
uses similar methods including solid phase peptide synthesis (SPPS), native
chemical ligation (NCL), S-alkylation and maleimide labeling, the methods will be
discussed in one section.

Project 1: Interactions of N-Terminally Acetylated Histones
Importance and Significance Although histone N-terminal acetylation (N-ac)
was discovered in 1964, the functions of this modification have not been fully
characterized.4 Recently, Marmorstein and co-workers5 characterized the
molecular basis of an N-terminal acetyltransferase NatD, which only acetylates
histone H4 and H2A9. Initial evidence suggests that histone N-ac can alter histone
in protein bindings, but the potential binding partner(s) was unidentified.5
Identifying the binding partner(s) can help reveals the functions and mechanism of
gene regulation.
Purpose and Hypothesis The purpose of project 1 is to identify the binding
partner(s) of N-terminally acetylated histones. The Marmorstein group
hypothesized N-ac of histone H4 could change the binding affinity to its binding
partner(s) by N-ac, to trigger downstream activities. Therefore, there should be a
difference in protein binding between non-acetylated histone H4 versus N-ac
histone H4. It was anticipated that at least one protein target could be identified
from the photo-crosslinking experiment, possibly a transcription factor or an
enzyme that deacetylates the N-ac histone.
Experimental Design To find the putative unknown binding partner(s)
regulated by histone H4 N-ac, a photo-crosslinking experiment to crosslink histone
H4 with proteins in the cell lysates was proposed. By comparing the binding
partner(s) between non-acetylated with N-ac histone H4, protein(s) that shows
binding preferences towards one type of histone H4 could be identified. The photocrosslinking experiment requires a model that mimics the native structure of
histone H4. The Petersson laboratory devised a peptide probe consists of the first
22 N-terminal residues of the human histone H4 protein.6 Only the first 22 residues
were chosen to represent the histone H4 protein because the full length of histone
H4 protein is over 100 amino acids long, and synthesis of full-length protein is far
beyond the capacity of SPPS without the aid of ligation methods. To functionalize
the peptide probe, a photo-lysine residue and a biotin tag were incorporated into
the sequence. The photo-lysine is a diazirine photo-crosslinker, developed by
Yang and co-workers.7 In photo-lysine, the diazirine group is embedded in the
lysine sidechain, having close structural proximity to the native lysine. The
Petersson laboratory previously synthesized histone H4 peptide with
benzophenone photo-crosslinker, then a photo-crosslinking experiment was
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performed by the Marmorstein group. Due to non-specific binding, no useful data
could be extrapolated (Marmorstein laboratory, University of Pennsylvania, PA,
USA, unpublished work, 2016). Compared to the benzophenone, the photo-lysine
can replace the natural lysine residue with minimal perturbation to the native
peptide, and hence generate more biologically relevant data. The diazirine is also
more reactive than benzophenone and the binding study requires a shorter UV
irradiation time. The reduction of time can also reduce non-specific binding
between the probe and the cell lysate. Therefore, the photo-lysine was chosen as
the photo crosslinker in this study. The biotin tag was introduced at the C-terminal
end of the peptide probe to pair with the photo-lysine for pull down experiments.
My task in this study was to synthesize the probe, and the photo-crosslinking
experiment was performed by the Marmorstein laboratory.
Background in Histones N-Terminal Acetylation In eukaryotic cells, histones
provide the scaffolds for wrapping and compacting DNA and to form the structure
of nucleosomes. Histones play critical roles in gene expression and are highly
regulated by amino acid sidechain post-translational modifications (PTMs), which
have been studied extensively in the past few decades. Different PTMs patterns
can trigger distinct downstream effects.8 Therefore, the function of a specific PTMs
is only meaningful in the context of a peptide or protein. A particularly elegant
approach to study the function of PTMs patterns is to use synthetic peptides with
defined amino acid sidechain modifications. For example, Muir and co-workers9
synthesized histone proteins H2B with ubiquitylated lysine 120 and then evaluated
the effect on protein recruitment and gene transcription. In many cases, PTMs in
this histone protein resulted in the recruitment of target proteins for gene regulation.

Figure 2. Space-filled PHD12 Structure, Highlighting the H3K14ac Peptide (yellow)
Bound Across the Unified Structure of PHD1 (green) and PHD2 (blue).15
Source: Adapted with permission from Zeng, L.; Zhang, Q.; Li, S.; Plotnikov, A. N.; Walsh,
M. J.; Zhou, M. Mechanism and Regulation of Acetylated Histone Binding by the Tandem
PHD Finger of DPF3b. Nature 2010, 466 (7303), 258–262. Copyright 2017 Nature
Publishing Group.

The function of histone sidechain acetylation was characterized. For example,
the H3K14ac modification can change the histone binding to PHD finger motif
3

(Figure 2). Compared to sidechain acetylation, the effect of protein N-ac has not
been fully characterized. In N-ac, an acetyl group from acetyl-coenzyme A (AcCoA) is transferred to the α-amino group on the first residue of the protein substrate.
N-acetylation occurs on about 80% of human proteins, either post- or cotranslationally.10 The functions of N-ac are related to protein stability, translocation,
and protein binding.11,12 Shemorry and coworkers reported that N-ac is one of the
many factors affecting the ubiquitination pathway.9 Depending on other conditions,
N-ac can either stabilize the protein or act as a degradation signal.13,14
There is some preliminary evidence showing histone N-ac can change its
protein binding partners. Marmorstein and co-workers5 characterized the
molecular basis of an N-terminal acetyltransferase NatD, which only acetylates
histone H4 and H2A9. The role of NatD in gene regulation is not fully understood,
but initial evidence suggests that histone N-ac may regulate the binding of PHD
finger proteins. The PHD finger is a motif often related to chromatin-mediated gene
regulation. Another study by Zeng and co-workers15 showed that the PHD finger
can selectively bind to histones H3 and H4, where the interaction of the PHD
fingers with H3 is promoted by acetylation at lysine 14, but inhibited by sidechain
methylation at lysine 4. The differential binding of the PHD fingers alters the gene
transcription of mouse DPF3b downstream genes Pitx2 and Jmjd1c.

Project 2: Binding Study of (PR)x Peptide to Proteasome
Importance and Significance Amyotrophic lateral sclerosis (ALS, or Lou
Gehrig's disease) is a progressive, fatal neurodegenerative disease characterized
by the loss of motor neurons in the brain and spinal cord.16 The prevalence of ALS
is about 5 cases per 100,000 people and death occurs typically 3–5 years after
diagnosis. Riluzole17 and Edaravone18 are the only ALS medicaitons approved by
FDA. The mechanism of ALS is not fully understood, mutations of several genes
can lead to the development of ALS.19 The microsatellite expansion in C9ORF72
gene was found to be the most important cause of ALS, which accounts for
approximately 34.2% of ALS cases.20,21 Undestanding of the mechnism of the
C9ORF72 gene can provide thoerical background for ALS treatments
development.
Purpose and Hypothesis The C9ORF72 gene is transcribed via a repeatassociated non-AUG (RAN) translation mechanism, where translation can occur
in both sense and anti-sense transcripts. The translation products of C9ORF72 are
five different poly-dipeptides: glycine-alanine (GA), glycine-arginine (GR), prolinearginine (PR) proline-alanine (PA), and glycine-proline (GP). The length of the
peptides varies among patients, so PRx is used to represent peptides without
defined length.
There are two theories about the mechanism of the disease. The RNA toxicity
theory suggests the disease is the result of RNA toxicity from C9ORF72
transcription.22 In contrast, the peptide toxicity theory suggests that cell death is
caused by the translation products of C9ORF72.23 Shi and co-workers24 reported
that the toxicity of the PRx peptide comes from plugging the nuclear pore, and
prehibiting communication between the nucleus and cytoplasm. In their study, the
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stimulated emission depletion (STED) microscopy image shows co-localization of
the nucleoporin gp210 and the PR20 peptide indicates the PR20 peptide is binding
to the nuclear pore, as shown in Figure 3.

Figure 3. Merged Confocal Microscopic Image of Fluorescein Isothiocynate
Labeled PR20 Peptide (red) and STED Image of Nucleoporin gp210 (green).25
Source: Adapted with permission form Taylor, J. P. A PR plug for the nuclear pore in
amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. 2017, 114 (7), 201621085. Copyright
2017 PNAS.

A separate study by Kalb and co-workers26 reported that the PRx peptide binds
to the proteasome to inhibit degradation of ubiquitinated substrates, which leads
to cytotoxicity. These results do not necessarily conflict with each other; it is
possible that the PRx peptide can bind to several targets in cells. This is likely,
given its very simple sequence.
The Kalb group hypothesized that the PRx peptide can bind to certain subunit(s)
of the proteasome, possibly by plugging the proteasome entrance site and
resulting in cytotoxicity. This hypothesis can be confirmed by identifing the binding
pattern of PR20 to the proteasome using photo-crosslinking probes.The Kalb group
also expect that the PRx peptide can colocalize with the proteasome in the cell for
the binding event to occur. The second hypothesis can be confirmed by observing
the colocation of a fluorocence PR20 peptide with protesome in cell under a
confocal microscope. My taks in this project was to develop the chemical probes
needed for the in vitro experiments. All in vitro experiments was performed by the
Kalb group.
Experimental Design To confirm the hypothesis that the PRx peptide can bind
to certain subunit(s) of the proteasome, a photo-crosslinker probe can be used to
identify the binding partners(s) of PR20 peptide. Similar to project 1, a photocrosslinking probe with a photo-crosslinker and a biotin tag was incorporated into
the PR20 peptide. Since it is difficult to perform the PR20 peptide sidechain
modification, the photo-corsslinker and biotin tag was added to the terminal of the
sequence. In the fluorocence PR20 peptide design, a fluorophore was attached to
a PR20 peptide at the C-terminal.

Methods in Peptide Synthesis and Functionalization
One advantage of peptide synthesis and modification is that once the standard
protocols are established, peptides with desired sequence, functional groups and
5

structure can be synthesized by the same approach. The methods described
below apply for both Chapter 1 and Chapter 2.
Peptide Backbone Construction and Peptide Modification Solid phase
peptide synthesis (SPPS) can generate short peptides fragments. The maximum
length of peptide generated by SPPS is around 40 amino acids with useful yield.
Longer peptides or proteins can be synthesized by recombinant protein expression
or by ligation of shorter fragments. Among different ligation methods, Native
Chemical Ligation (NCL) is the most popular method to form a native amide bond
between the two fragments, by joining a C-thioester peptide fragment to an Ncysteine modified peptide fragment.
Installing chemical modifications depends on the nature of the modification.
Some chemical modifications can be installed during SPPS by using unnatural
amino precursors. In protein expression, unnatural amino acid mutagenesis can
be used. Since unnatural amino acid mutagenesis is typically restricted to the
inclusion of a single non-natural amino acid, we will restrict our discussion to SPPS
and ligation. If the modification is unstable in SPPS condition or too large and
sterically hindering to the next coupling reaction in SPPS, other methods such as
click reactions and cysteine S-alkylation can be used to install those
modifications.27,28
Backbone Construction by Solid Phase Peptide Synthesis (SPPS) First
introduced by Merrifield and co-workers29 in 1963, solid phase peptide synthesis
(SPPS) has become the most popular synthetic approach for making short
peptides. The yield of stepwise SPPS decrease as the length of peptide chain
increases. In general, the maximum length of the peptide with useful yield is
around 40 amino acids. The use of solid support has huge advantages over
solution phase peptide synthesis, for the latter often requires purification after each
standard synthetic cycle and overnight reactions. SPPS eliminates the purification
steps in each synthetic cycle. SPPS can be accelerated to 4 minutes per synthetic
cycle,30 and performed by automation at small scale or at industrial scale.31
Based on the choice of N-terminal protecting group, SPPS can be divided into
two strategies: tert-butyloxycarbonyl (Boc) strategy and 9H-fluoren-9-ylmethoxycarbonyl (Fmoc) strategy. The Boc strategy is the original method
developed by Merrifield, which uses the Boc protecting group as the N-terminal
protecting group. The Boc group is removed in mild acid condition. The negative
aspect of the Boc strategy is that it requires the use of hazardous hydrofluoric acid
(HF) to remove sidechain protecting groups and cleavage from the solid support.29
On the other hand, the Fmoc strategy uses a base liable N-terminal protecting
group. The removal of sidechain protecting groups and cleavage from the solid
support is achieved by treatment with trifluoroacetic acid (TFA), which is a much
milder condition compare to HF. The Fmoc strategy is more popular than the Boc
strategy for safety reasons, and the Petersson laboratory uses the Fmoc strategy
exclusively. Figure 4 shows the typical synthetic cycle of Fmoc based SPPS
synthesis, where PG stands for a generic side-chain protecting group and AA
stands for a generic amino acid. The C-terminal amino acid is first attached to the
resin via a cleavable linker. In the next step, the Fmoc N-terminal protecting group
is removed by base without removing the acid liable side-chain protecting groups.
6

The peptide chain is extended by coupling the next amino acid after removal of
reaction side products and excess reagents by rinsing and filtration. The same
deprotecting and coupling process is cycled until the completion of the entire
sequence of the peptide. At the end of the cycle, the cleavage from the solid
support and the side-chain protecting groups are typically removed simultaneously.
The synthesized crude peptide is often purified by precipitation and Highperformance liquid chromatography (HPLC), then lyophilized to a powder. For
peptides requiring ligation steps, NCL is often used to link fragments of peptides.
Backbone Extension by Native Chemical Ligation Developed by Kent and
co-workers32 in 1994, NCL can be used to ligate two peptide fragments with a
native peptide bond without epimerization.33 NCL is mostly used to ligate peptides
that are too long for SPPS or even an expressed protein to a synthetic peptide
fragment. The main advantage of NCL is its selectivity towards a thioester and Nterminal cysteine, allowing both peptide fragments to be unprotected. Using
unprotected peptides eliminates steps for protection/deprotection and prevents
solubility issues associated with bulky hydrophobic sidechain protecting groups. In
addition, NCL is a convenient one-pot reaction with a high conversion rate. NCL
has expanded the application of SPPS and enabled the synthesis of long peptides
or even full-length proteins.
Figure 5 shows the steps of the NCL method commonly employed in the
Petersson laboratory.34,35 Fragment A is a C-terminal modified peptide hydrazide
generated from modified 2-chlorotrityl chloride resin, fragment B is a peptide with
an N-terminal cysteine. First, the acyl hydrazide group from the fragment is
converted to an azide group, then converted to a peptide thioester by 4mercaptophenylacetic acid (MPAA) (Figure 5B). Next, the thiol group of the Nterminal cysteine of fragment B attacks the peptide thioester and forms a native
peptide bond via an N- to S- acyl shift (Figure 5C). To prepare the peptide
hydrazide, the 2-chlorotrityl chloride resin is treated with hydrazine hydrate before
loading the first amino acid, as shown in Figure 5A.35 The SPPS product of
modified resin gives the C-terminal peptide hydrazide. If the thiol group from the
cysteine is not desired in the final product, the thiol group can be removed by
desulfurization.36 Desulfurization greatly extends the possible ligation sites of NCL.
Besides NCL, there are other traceless peptide ligation methods, such as traceless
Staudinger ligation37 and methionine ligation.32,38 All ligation methods involve a
chemo-selective capture step followed by an invariable intramolecular acyl transfer
reaction. These steps are followed by a final variable step to convert the auxiliary
to a natural amino acid.

7

Figure 4. Scheme of Fmoc Based SPPS.39
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Figure 5. Native Chemical Ligation Scheme.35 (A) Generation of hydrazine
modified 2-chlorotrityl chloride resin. (B) Generation of peptide thioester
from peptide hydrazide, and (C) Peptide bond formation.

Common Peptide and Protein Modification Methods. After the construction
of the peptide backbone, residues can be modified at various reactive sites.
Cysteine is a common handle for modifying peptides. There are several
approaches to conjugate building blocks or modify at the cysteine residue. Salkylation and maleimide crosslinking are the two methods that were used in this
study. Other possible methods include solid phase cross-coupling40 and enzymecatalyzed macrocyclization41.
S-alkylation conjugates the peptide with the fragment of interest at the cysteine
thiol sidechain, establishing a thioether bond at basic conditions.27 Figure 6 is an
example of using S-alkylation to couple an alkyne to the cysteine residue sidechain.
The linker is small but the requirement for basic reaction conditions is not suitable
for base labile molecules.

Figure 6. S-alkylation of Cysteine Containing Peptide.27 A represents a protein or
peptide with a cysteine.
Maleimide crosslinking is a common method to label a protein with a biotin or a
fluorophore.42 This method is also used to generate antibody−drug conjugates for
cancer treatment.43 The main advantage of maleimide crosslinking reaction is the
reaction can occur in neutral aqueous conditions. One negative aspect of
maleimide crosslinking is it leaves a relatively large linker compared to S-alkylation,
as shown in Figure 7.

Figure 7. Maleimide Crosslinking Reaction.43 A represents a labeling reagent with
the maleimide reactive group; B represents a protein or other molecule that
contains the target functional group.
Azide-Alkyne Click Chemistry Even though cysteine is a useful handle for
bioconjugation, selectively labeling peptides or proteins with multiple cysteine
residues is non-trivial. In this case, click chemistry is another common peptide and
protein modification method. The term "click chemistry" does not refer to one
specific reaction, rather, any ligation reaction that is robust, easy to perform, with
high yield, minimum byproducts formation, and broad substrate spectrum can be
referred to as a “click chemistry reaction”. The classical click chemistry reaction is
the copper catalyzed azide-alkyne cycloaddition shown in Figure 8, in which a Cu(I)
catalyst is generated from Cu(II) in situ.44 The main advantage to this reaction is
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that there are no azides or alkynes in most biological systems, so this reaction can
be selective in biomolecules like proteins, and can even occur in vivo without
perturbing the biological system (although Cu(I) can be toxic).45 More importantly,
the copper catalyzed click reaction is orthogonal to S-alkylation and maleimide
crosslinking, which enable us to selectively modify peptides and proteins at
multiple sites.

Figure 8. Scheme of Click
hydroxypropyltriazolylmethyl)amine.

Reaction.

46

THPTA

refers

to

3-

Figure 9. Mechanisms of Photo-crosslinking.47 (A): benzophenone based
crosslinking. (B): diazirine based crosslinking. Lig refers generic ligands.
Photo-Crosslinking Probes for Protein-protein Interaction Studies
Unnatural amino acids can be introduced during SPPS or at modification steps.
One class of unnatural amino acids is photo-crosslinkers. A photo-crosslinker can
generate a covalent linkage between the ligand and the binding target based on
spatial proximity under UV irradiation. The captured target(s) can be isolated and
identified by mass spectrometry (MS),48 which can be useful in drug design and
protein function studies. Common photo-crosslinkers can be characterized into
three families: benzophenone, aryl azide, and diazirine. These photo-crosslinking
groups have differing selectivity and reactivities.47 The mechanism of
benzophenone and diazirine crosslinking is shown in Figure 9. In both cases, UV
irradiation generates a reactive radical, but the homolytic bond cleavage of
benzophenone is reversible, allowing it to return to the ground state if no reactive
partner is present. On the other hand, the expulsion of N 2 in diazirine photolysis
11

makes it irreversible, so the resulting carbene is much more reactive. Thus,
benzophenones are more selective crosslinkers.
Using the methods of peptide synthesis and modification mentioned above, I
synthesized a series of probes to study the functions of histone H4 N-terminal
acetylation (N-ac) in project 1. The result of project 1 can help explaining the role
of histone co- and post-translation in gene regulation. In project 2, I synthesized a
different set of probes to study the toxicity mechanism of proline-arginine tandem
repeat peptides PRx. The result of project 2 can provide mechanism foundation for
developing amyotrophic lateral sclerosis (ALS) treatments.

Materials and Methods
SPPS Materials Fmoc-Lys(biotinyl)-OH was purchased from TCI America
(Portland, OR, USA). Fmoc-PhotoLys(Boc)-OH was kindly provided by Dr. Xiang
David Li from the University of Hong Kong (Hong Kong, China). 2-(1Hbenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU), 2Chlorotrityl chloride resin (100-200 mesh, 1% DVB) were purchased from
Novabiochem (currently EMD Millipore; Billerica, MA, USA). Standard amino acids
for Fmoc peptide synthesis were also purchased from Novabiochem (currently
EMD Millipore; Billerica, MA, USA), including Fmoc-Ala-OH, Fmoc-Arg(Pbf)-OH,
Fmoc-Gly-OH, Fmoc-His(Trt)-OH, Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-PheOH and Fmoc-Pro-OH. Piperidine was purchased from American Bioanalytical
(Natick, MA, USA). Sigmacote®, N,N-diisopropylethylamine (DIPEA), and
Trifluoroacetic acid (TFA) were purchased from Sigma-Aldrich (St. Louis, MO,
USA). Glass peptide synthesis reaction vessels (RVs) were treated with
Sigmacote® prior to use. Triisopropylsilane (TIPS) was purchased from Santa
Cruz Biotechnology (Dallas, TX, USA). N-Methylmorpholine (NMM) and 4mercaptophenylacetic acid were purchased from Acros (Currently Fisher Scientific,
Hampton, NH, USA). Acetic anhydride, hydrazine hydrate (55% in water), BondBreaker™
TCEP
Solution,
Ellman’s
reagent,
Acetonitrile
(ACN),
Dimethylformamide (DMF), Methanol (MeOH) and Tetramethylrhodamine-5Maleimide (TAMRA) were purchased from Fisher Scientific (Hampton, NH, USA).
Guanidine hydrochloride (Gn·HCl) was purchased from Invitrogen (Carlsbad, CA,
USA) Cys(ProArg)20 peptide was purchased from GenScript (Piscataway, NJ,
USA).
Instruments Histone H4 peptide residues 1 to 18 was synthesized using a
Liberty synthesizer (CEM Corporation, Matthews, NC). Crude peptides were
purified with a Varian ProStar High-Performance Liquid Chromatography (HPLC)
instrument outfitted with a diode array detector (currently Agilent Technologies)
using aqueous A (H2O + 0.1% TFA) and organic B (CH3CN + 0.1% TFA) phases.
Purification testing was performed in an Agilent 1100 Series HPLC with a 4.6nm
Phenomenex Luna C8 (2) column.
UV absorbance spectra were obtained with a Hewlett-Packard 8452A diode
array spectrophotometer (currently Agilent Technologies; Santa Clara, CA, USA).
Matrix-assisted laser desorption ionization (MALDI) mass spectrometry (MS) data
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were collected with a Bruker Ultraflex III MALDI-TOF-TOF mass spectrometer
(Billerica, MA, USA).
Reagent Setup TFA cleavage cocktail A: TFA/DCM/TIPS/Water=90/5/2.5/2.5
(vol/vol/vol/vol) TFA cleavage cocktail B: TFA/DCM/TIPS/Water=85/10/2.5/2.5
(vol/vol/vol/vol) TFA cleavage cocktail C: TFA/DCM/TIPS/Water=30/65/2.5/2.5
(vol/vol/vol/vol) Acylating cocktail: DMF/NMM/acetic anhydride=84/6/10
(vol/vol/vol/vol) 5% Hydrazine in DMF: 0.4 mL of hydrazine hydrate was mixed with
7.6 ml of DMF. TAMRA-maleimide in DMSO: TAMRA-maleimide was dissolved in
DMSO to a final concentration of 4.5 mM. Two different phosphate solutions (0.2M)
containing 6M Gn•HCl (pH 3.0-3.1 and pH 6.9-7.0, respectively): For a 10-ml
solution, 312 mg of NaH2PO4•H2O and 5.74 g of Gn•HCl was mixed into a 15-ml
centrifuge tube and pH was adjusted to 3.0-3.1 and 6.9-7.0 with 6M NaOH and 1M
HCl. The solution was filtered by 0.22 µm microporous membrane filter. NaNO2,
0.5M: 17mg of NaNO2 was dissolved in 0.5 ml of water before use. 50% ACN in
water with 0.1%TFA: 5 ml of water, 5ml of CAN and 10 µl of TFA were mixed. 15 °C ice bath was prepared by mixing 12.5 g of NaCl with 25 g of ice. Milli-Q
filtered (18 MΩ) water was used for all solution preparations (EMD Millipore,
Billerica, MA, USA).
Standard Synthesis Cycle Standard synthesis cycle was used for all
deprecating and coupling reactions except the first amino acid and unnatural
amino acids. In each synthesis cycle, the resin was washed three times with
(dimethylformamide) DMF under gentle agitation. Followed by three washes of
dichloromethane (DCM) and another three washes of DMF. To remove the Fmoc
deprotecting group, 2 ml of 20% piperidine in DMF (vol/vol) was added to the
reaction vessel (RV) and agitated for 20 minutes. Then the resin was drained and
washed with the same DMF-DCM-DMF sequence as mentioned above. For each
25 µmol scale synthesis, 125 µmol (5 equiv) of the appropriate amino acid and
125µmol of HBTU (5 equiv) was dissolved in 2 ml of DMF, with 44 µl of DIPEA (10
equiv) added. This step pre-activates the amino acid and usually gives the solution
a light-yellow color. The fully dissolved amino acid solution was then added to the
RV. The coupling reaction time is 30 minutes. This cycle was repeated until the full
length of peptide is synthesized. After the last amino acid coupling, step 1-6 was
performed to remove the Fmoc group.
Synthesis of PR3 and PR5 Peptides 7, 8 PR3 and PR5 peptides were
synthesized in 25 µmol scales each, using 2-Chlorotrityl chloride resin under
standard SPPS condition. To couple on the first amino acid, 42mg of 2-Chlorotrityl
chloride resin (estimated resin loading capacity of 0.6mmol/g) was added to a dry
reaction vessel (RV) with prior Sigmacote® treatment. Then the resin was washed
with DMF and then swelled in DMF for two successive of 15 minutes with gentle
agitation. Then 125 µmol (5 equiv) of Arg(Pbf) was dissolved in 2 ml of DMF, then
the amino acid solution and 44µL of DIPEA (10 equiv) were added to RV. The 2Chlorotrityl chloride resin does not require HBTU in the first amino acid coupling
step. The coupling time was 30 minutes. The rest of the sequence was synthesized
using the Standard Synthesis Cycle. After the final Fmoc deprotection, the resin
was drained and dried by vacuum filtration. To remove the Pbf protecting group
and cleaved from the resin, 2ml of TFA cleavage cocktail A was added to the RV
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and agitated for 90 minutes. At the end of the cleavage, the cleavage solution was
collected from the bottom of the RV, and then two small amounts of DCM were
added to rinse the RV. The combined cleavage solution was concentrated by a
rotavapor. The concentrated peptide was diluted to 5 ml with 50% ACN in water
with 0.1%TFA. The crude peptide was then filtrated with a 0.20µM syringe filter to
remove solid particles before HPLC purification.
PR3 and PR5 Peptide Purification and Characterization The crude peptides
were purified by reverse-phase HPLC using a Vydac 218TP C18 prep column
(Grace/Vydac; Deerfield, IL, USA). The flow rate was 15 ml/min, the gradient was
2%B in 0-5 min, 2-10%B in 5-10 min, 10-40%B in 10-40 min, 40-100%B in 40-45
min, 100%B in 45-50 min, and 100-2%B in 50-55 min, where A is water with 0.1%
TFA and B is ACN with 0.1% TFA. Fractions were tested by MALDI-MS, fractions
with pure peptide were combined and lyophilized. The lyophilized products were
dissolved with 5.2 ml of 50% ACN in water (0.1%TFA), then 5 ml of the solution
was transferred to five microcentrifuge tubes with 1 ml solution in each tube. The
microcentrifuge tubes were dried down with a table top vacuum centrifuge
(Savant/Thermo Scientific; Rockford, IL, USA). The rest of the solution was used
for MALDI characterization and analytical HPLC analysis. For HPLC
characterization, the sample was diluted to 800 µL final volume with water with 0.1%
TFA. MALDI characterization was performed using standard instrument set-up
under positive mode with reflector enabled, using α-Cyano-4-hydroxycinnamic
acid (CHCA) matrix. HPLC analysis was performed using a 4.6mm VYDAC HPLC
C18 column from Grace Davison Discovery Science at 1 ml/min flow rate,
measuring absorbance at 215 nm, using the same gradient in protein preparation.
Systhesis of Histone H4 Peptides 1, 2 Synthesis of Histone H4 peptide uses
the synthesis cycle as above, with minor differences in certain amino acids
coupling steps mentioned below. For Lys(biotinyl), 3 equiv of the amino acids for
coupling reaction was used. For Photo-Lysine, we used 2 equiv of the amino acids
in coupling reactions. 5 equiv of the Fmoc amino acids for all other amino acids.
Residues 2-18 were synthesized by the Liberty peptide synthesizer following
manufactory’s procedures. For the first amino coupling, 84mg of 2-Chlorotrityl
chloride resin was added to a dry reaction vessel (RV) with prior Sigmacote®
treatment. 5 ml of 50% DMF in DMSO was added with magnetic stirring for two
successive of 15 minutes to swell the resin, then drained by vacuum filtration. Next,
120 mg of Fmoc-Lys(Biotin)-OH was added to 6 ml of 50% DMSO in DMF. To help
solubilization of the amino acid, the solution was warmed in 37 °C water bath for
about 15 minutes. 3 ml of the amino acid solution and 175 µl of DIPEA were added
to the RV. After 45 minutes of coupling, the resin was drained by vacuum filtration.
The rest of Fmoc-Lys(Biotin)-OH solution and 175µl of DIPEA were added to the
RV. After 45 minutes of coupling, the resin was drained and washed by the DMFDCM-DMF sequence as mentioned before. After loading the first amino acid to the
resin, the resin was swelled in 6 ml of DMF for 30 minutes then drained. To
deactivate the unreacted site on the resin, a capping procedure was performed by
adding 2 ml of 10% MeOH/DMF and 175 µl of DIPEA to the RV. The capping
reaction was 20 minutes and then the resin was washed with the DMF-DCM-DMF
sequence. Next, the resin was transferred from the RV to the Liberty peptide
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synthesizer to synthesize residues 2-18 using manufacturer’s standard method.
After the 18th residue, the resin was removed from the peptide synthesizer and
manual synthesis was performed using the standard synthesis cycle, since the
photo-lysine is a light sensitive amino acid, the handling of photo-lysine and
reaction steps after photo-lysine coupling reaction were performed under red LED
with the RV covered with aluminum foil. After the final Fmoc deprotection reaction,
half of the resin was acetylated at N-terminal, giving the N-acetylated Histone H4
peptide. The other half of the resin undergoes cleavage directly. To acetylate the
peptide at the N-terminal. Two portions of 5 ml of the acylating cocktail were added
to the RV and agitated for 20 minutes with washing in between. To cleave the
peptide from the resin and remove the protecting groups, 2 ml of TFA cleavage
cocktail B was added to the RV and agitated for 90 minutes. At the end of the
cleavage, the cleavage solution was collected from the bottom of the RV, and then
two small amounts of DCM were added to rinse the RV. The cleavage solutions
were then concentrated using a rotavapor. The concentrated peptide solution was
transferred to a 15-ml centrifugal tube, and then about 10 ml of cold ether was
added to precipitate down the crude peptide. The volume of cold ether should be
at least 10 times larger than the concentrated peptide solution. The peptide was
incubated at 4 °C for 20 minutes and then centrifuged for 5 minutes. The
supernatant was discarded and the pellet was dissolved in minimal amount of 50%
ACN in water with 0.1%TFA. The crude peptide was then filtrated with a 0.20µM
syringe filter to remove solid particles before HPLC purification.
Peptide Purification and Characterization The crude peptides were purified
by reverse-phase HPLC using a Vydac 218TP C18 prep column (Grace/Vydac;
Deerfield, IL, USA). The flow rate was 15 ml/min, the gradient was 2%B in 0-5 min,
2-10%B in 5-10 min, 10-40%B in 10-40 min, 40-100%B in 40-45 min, 100%B in
45-50 min, and 100-2%B in 50-55 min, where A is water with 0.1% TFA and B is
ACN with 0.1% TFA. Fractions with pure peptide were combined and lyophilized.
The lyophilized products were dissolved with 5.2 ml of 50% ACN in water
(0.1%TFA), then 5 ml of the solution was transferred to five Eppendorf tubes with
1 ml solution in each tube. The Eppendorf tubes were dried down by a table top
vacuum centrifuge (Savant/Thermo Scientific; Rockford, IL, USA). The rest of
solution was used for MALDI characterization and analytical HPLC analysis. For
HPLC characterization, the sample was diluted to 800µL final volume with water
(0.1% TFA). MALDI and HPLC characterization was performed using the same
condition as for PR3 and PR5 peptides.
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Synthesis of TAMRA-PR20 Probe 3 Crude Cys(PR)20 peptide solid was
purchased from GeneScript (Piscataway, NJ, USA) and purified by reverse-phase
HPLC using a Vydac 218TP C18 prep column (Grace/Vydac; Deerfield, IL, USA).
The flow rate was 12 ml/min, the gradient was 2%B in 0-5 min, 2-10%B in 5-10
min, 10-40%B in 10-40 min, 40-100%B in 40-45 min, 100%B in 45-50 min, and
100-2%B in 50-55 min. The purified peptide was lyophilized. Quantification was
performed by using Ellman’s reagent following Sigma-Aldrich manual #22582, with
the exception that pretreatment with immobilized TCEP was not performed. 0.2
mmol of Cys(PR)20 peptide was dissolved in 900 µl of 20 mM Tris buffer, pH 8. 0.5
µl of TCEP bond breaker and 36 µl of TAMRA-maleimide in DMSO was added.
The reaction was performed at room temperature with magnetic stirring, using
MALDI-MS to monitor the reaction process. The labeled peptide 3 was purified
using the same condition for Cys(PR)20 peptide, followed by characterized with
MALDI-MS with expected m/z of 5652.

Preparation of Hydrazine Modified 2-Chlorotrityl Chloride Resin The
warhead 4 was synthesized by SPPS using hydrazine modified 2-Chlorotrityl
chloride resin. First, 100 mg of 2-Chlorotrityl chloride resin was added to a dry
reaction vessel (RV) with prior Sigmacote® treatment. The resin was swelled by
DMF for two successive of 15 minutes. Then, the resin is treated with two
successive of 4 ml of 5% (vol/vol) hydrazine in DMF for 20 minutes under gentle
agitation. The resin was washed with DMF and then DCM carefully.
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Synthesis of Warhead 4 To couple the first amino acid, 125 µmol (5 equiv) of
the appropriate amino acid and 125 µmol of HBTU (5 equiv) was dissolved in 2 ml
of DMF, then 44 µl of DIPEA (10 equiv) was added to the amino acid solution. The
amino acid solution was added to the RV and agitated for 30 minutes. The rest of
the sequence was synthesized by standard synthesis cycle. The cleavage and
purification condition was identical to the PR3 peptide. The expected m/z is 752,
monitored by MALDI-MS.

Synthesis of Molecule 5 0.6 µmol of peptide hydrazide 4 was dissolved with
0.4 ml of 0.2M phosphate buffer (pH 3) in a 2 ml microcentrifuge tube. pH was
adjusted to 3.0-3.1 with 6M NaOH and 1M HCl. The microcentrifuge tube was
incubated on -15 °C ice bath for 15 minutes. Around 0.5 µmol of Cys(PR)20 peptide
and 13.6 mg of MPAA (4-Mercaptophenylacetic acid were dissolved in 0.4 ml of
pH 7 phosphate buffer and adjusted pH to 6.5. To oxidize the peptide hydrazide to
azide, 40 µl of 0.5M NaNO2 solution was added to the solution of compound 4. The
pH of the mixture was adjusted to 3-3.1 and stirred for 15 minutes in -15 °C ice
bath. To convert the peptide azide to thioester, Cys(PR)20 and MPAA mixture
solution was added to peptide azide 4. The microcentrifuge tube was removed
from ice bath and warmed to room temperature. pH was adjusted to 6.8-7.0 with
6M NaOH. After overnight stirring at room temperature, 80 µl of TCEP bond
breaker was added. The mixture was diluted to 5 ml final concentration before
HPLC purification. For MALDI-MS characterization, 1 µl of the reaction mixture
was diluted 30 times with water. The product 5 was purified using the same HPLC
gradient to compound 3 and then lyophilized. The expected m/z is 5908.
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S-Alkylation 4 Lyophilized peptide 5 was dissolved in a round bottom flask with
1 ml of MeOH. With stirring, 10 µl propargyl bromide, 5 µl of DIPEA and 1 mg of
TCEP was added to the flask. The reaction progress was monitored by MALDI-MS
until finished. When the reaction is finished, MeOH was removed by a rotary
evaporator and product 4 was dissolved in 50% ACN in water and then purified by
HPLC using the same gradient to compound 3. The expected m/z is 5976.
Peptide Characterizations All peptides were characterized with MALDI-MS as
shown in Table 1. For all peptides, expected m/z was observed, which suggests I
have successfully synthesized the peptides of interest.
Table 1. Characterizations of Synthetic Peptides
Molecule
Calculated (+m/z)
Measured (+m/z)
3
5652
5652
4
752
752
5
5908
5908
6
5976
5976
7
778
778
8
1284
1284
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Results and Discussion
Project 1: Interactions of N-Terminally Acetylated Histones
For comparison between the non-acetylated histone H4 peptide and N-ac
histone H4 peptide, two versions of the probe was designed. The non-acetylated
version is referred to as compound 1 and N-ac version as compound 2. The
sequence is R-Ser-Gly-Arg-Gly-PhotoLys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-GlyAla-Lys-Arg-His-Arg-Lys-Gly-Gly-Lys(Biotin)-COOH. R refers to a hydrogen atom
for non-acetylated histone peptide H4 probe 1 and an acetyl group for N-ac histone
peptide H4 probe 2. The structures are shown in Figure 10.
Peptide 1 and 2 were synthesized by SPPS and characterized by MALDI-MS.
We observed m/z of 2457 and 2499 for compound 1 and 2 on MALDI-MS,
respectively. This two masses correspond to [M+H]+ minus 28 Da, the minus 28
Da is the loss of two nitrogen atoms from diazirine functional group, which is
expected for the unstable crosslinking group.49 The MS data confirmed that I have
successfully synthesized the peptides of interest, and the peptides were used in in
vitro crosslinking experiments.
Cell Lysate Western Blot The cell lysate crosslinking test was performed by
Gleb Bazilevsky in the Marmorstein group and the result is shown in Figure 11. In
brief, the probes were incubated with cell lysates under UV irradiation, then a
streptavidin Western blot was performed to image the captured protein(s). The
photo-crosslinking experiments were performed with E. coli cell lysate and Hela
cells lysate, respectively. In the E. coli cell lysate pull-down experiment, no
difference was observed between the treatment with peptide 1 and 2, indicating no
protein shows binding preferences between the two versions of histone H4 peptide
in E. coli. The result that proteins from prokaryotic E. coli do not bind to the histone
H4 peptide meets the expectation since histone proteins only exist in eukaryotic
organisms. Thus, this serves as an effective negative control for non-specific
binding of the peptides. For the HeLa cell lysate pull-down experiment, a few bands
were found only in lane 12 (the N-ac H4 peptide) but not in lane 10 (the nonacetylated H4 peptide). This suggests that proteins bind exclusively to the N-ac H4
peptide. The identities of the protein bands have not yet been determined by MS.
It is concerning that many of the bands in lane 12 are also present in lane 11, nonirradiated N-ac H4 peptide. Further experiments are necessary to fully characterize
these interactions. I hypothesize that the identified protein might be an enzyme
that can remove the N-terminal acetyl group or a transcription factor.
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Figure 10. Design of Histone H4 Peptide Probe

1 2 3 4 5 6 7 8 9 10 11 12

Figure 11. Cell lysate Western Blot experiment. Lane 1 to 6 is E. coli lysate with
either 0 or 30 min UV irradiation. Lane 7 to 12 are HeLa cell lysate with either 0 or
30 min UV irradiation. Lane 1: cell lysate only, no probe, 0 min; Lane 2 cell lysate
only, no probe, 30 min; Lane 3: none-acetylated H4 peptide, 0 min; Lane 4: nonacetylated H4 peptide, 30 min; Lane 5: N-ac H4 peptide, 0 min; Lane 6: N-ac H4
peptide, 30 min; Lane 7: no peptide, 0 min; Lane 8: no peptide, 30 min; Lane 9:
non-acetylated H4 peptide, 0 min; Lane 10: non-acetylated H4 peptide, 30 min;
Lane 11: N-ac H4 peptide, 0 min; Lane 12: N-ac H4 peptide, 30 min. (Bazilevsky,
G. University of Pennsylvania, PA, USA. Unpublished work, 2016)
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Project 2: Binding Study of (PR)x Peptide to Proteasome
PR20 Probe for Cell Imaging Several peptides were synthesized to investigate
the toxic effects of (PR)X peptides, including their localization in cells and their sites
of interaction with the proteasome. To perform a fluorescence microscopy imaging
study, probe 3 was designed and synthesized to monitor the location of the peptide
in cells. This probe can also be used to determine the affinity of the probe for
purified proteasomes using flurescemce polarization. This probe consists of the
PR20 peptide with a fluorophore attached at one end. In probe 3 design, a
tetramethylrhodamine-5-Maleimide (TAMRA) fluorophore (highlighted in red) is
linked to the N-terminal cysteine of the PR20 peptide via maleimide crosslinking
(Figure 12). I chose TAMRA as the fluorophore because of its red fluorescence
can be distinguished from the GFP labeled proteasomes expressed in cells. The
proposed experiment is to add TAMRA-labeled probe 3 to the cell growth media,
and the cellular uptake and localization of probe 3 can be monitored by a confocal
microscope. Colocalization of probe 3 with the proteasome in cells can support the
proteasome toxicity theory.

Figure 12. Synthesis Route of TAMRA-PR20 Probe 3
Development of Photo-Crosslinking PR20-X Probe To verify the hypothesis
that the PRx peptide can bind to certain subunit(s) of the proteasome, a second
probe was designed and synthesized, which consists of a PR20 peptide, a photocrosslinker, and a biotin affinity purification tag. The identification of the binding
site(s) can provide critical information on the molecular mechanism of PR20 toxcity.
It could also be used in design of PR20 peptide binding antagonists, a potential
treatment for ALS.
Previously, Xing Chen from the Petersson group synthesized a photocrosslinking probe by using NCL to ligate a PR20 peptide to a “warhead”. The
warhead is a short peptide containing a biotin (highlighted in red) and a
benzophenone group (highlighted in blue), with a glycine residue in between each
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functional motif (Figure 13). This probe is referred to as the PR20-X probe. I
synthesized a batch of the PR20-X probe as a replicate to Xing Chen’s work.

Figure 13. PR20-X Probe Design. (Petersson laboratory, University of
Pennsylvania, PA, USA. Unpublished work, 2016).
Development of Photo-Crosslinking Probe with a Bio-orthogonal Handle
In the PR20-X probe design, the warhead is linked to the C-terminal end of the PR20
peptide. One negative aspect of this probe design is there is a cysteine residue in
the sequence, and the cysteine thiol group can potentially form disulfides or bind
to the proteasome non-specifically. To overcome this problem, probe 4 was
designed to verify the result obtained from using the PR20-X probe (Figure 14).
Probe 4 has similar functional groups to PR20-X, but the warhead is linked to the
N-terminal end instead of the C-terminal end of the PR20 peptide. If the proteasome
binding patterns of PR20-X and 4 are consistent, we can conclude that the binding
of the PR20 peptide to the proteasome subunits is not an artifact due to the
placement of warhead. Otherwise, the probe design must be modified so that the
probe does not perturb the function of the PR20 peptide. Probe 4 also contains a
click reaction handle at the cysteine residue, so that the cysteine thiol group can
be neutralized. Neutralizing this reactive thiol group not only prevents non-specific
binding but also provides a click handle for fluorophore attachment. The
fluorophore attached probe 4 can be a substitute to probe 3. For the photocrosslinker, benzophenone was chosen because benzophenone is more stable
than the diazirine photo-crosslinker used in project 1, and therefore the peptide
probe is likely to have selective crosslinking. The peptide is also more stable under
ambient light.
The synthesis route of 4 is summarized in Figure 14. First, warhead 5 was
synthesized by SPPS, then 5 was ligated with the Cys(PR)20 peptide to form
compound 6, followed by S-alkylation with propargyl bromide to form the final
product 4. I expected that probe 4 could bind to certain proteasome subunit(s) in
the same manner as PR20-X. The band from the blotting experiment can be further
analyzed by MS to identify the proteasome subunit.
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Figure 14. Synthesis Route of Warhead-PR20 Probe 4
The preparation of the PR20 peptide suffers from low yield and difficulties in
quantification. I initially synthesized the PR20 peptide by using a CEM Liberty
peptide synthesizer but less than 1% yield product was recovered. One reason for
the low yield is the length of the PR20 peptide is at the maximum limit of SPPS. As
the peptide chain grows, the polymer may aggregate or become sterically
inaccessible, and prevents further chain extension. Another reason is that the
arginine 2,2,4,6,7-Pentamethyldihydrobenzofuran-5-sulfonyl (Pbf) protecting
group is not very acid lable, the removal of Pbf groups requiring prolonged
treatment of high concentration TFA. However, the same condition can also
hydrolyze the peptide backbone, so the deprotection time was limited to a few
hours. As a result, we observed incomplete deprotection by-products from the
crude peptide, having an m/z of 252 Da or 504 more than the expected mass. 1,2Dimethylindole-3-sulfonyl (MIS) was reported to be a more acid lable substitution
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for the Pbf group, but there is no commercially available Fmoc-Arg(MIS)-OH amino
acid in the market as of 2017.50
In probe 4 synthesis, the Cys(PR)20 peptide was quantified by Ellman’s reagent
without pretreatment. According to Ellman’s reagent standard protocols (SigmaAldrich manual #22582), the peptide should be treated by immobilized TCEP to
remove possible disulfide bonds. However, I could not elute the peptide from the
immobilized TCEP resin. The most likely reason is that the guanidinium group from
the arginine sidechain binds to the resin tightly, preventing elution from the resin.
Without TCEP treatment, the quantification will underestimate the concentration of
the Cys(PR)20 peptide. To compensate for this problem, I used an excess amount
of the compound 5 during the NCL process.

Figure 15. PR20 Peptide Crosslinks to Proteasome Subunits. Lane 1: proteasome
crosslinked with the PR20-X probe. Lane 2: same to lane 1 plus excess unlabeled
PR20 peptide to compete off PR20-X probe binding. Lane 3: proteasome
crosslinked with the PR20-X probe plus an excess amount of unlabeled GR20
peptide. Lane 4: Coomassie stained proteasome subunits. The red boxes indicate
the corresponding bands from lanes 1 and 2 to lane 4. (Kalb, R. Children's Hospital
of Philadelphia, PA, USA. Unpublished work, 2016).
Proteasome Binding Assay The proteasome binding assay using the PR20-X
probe was performed by the Kalb group from the Children's Hospital of
Philadelphia. Figure 15 is a streptavidin Western blot of proteasome subunits,
where the probes and the cell lysate were crosslinked by UV irradiation, then
separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS
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Page) (Kalb, R. Children's Hospital of Philadelphia, PA, USA. Unpublished work,
2016). The three clear bands in lane 1 suggested that three proteasome subunits
can bind to the PR20-X probe, labeled as 1, 2, and 3. The bands are less intense
in lane 2, suggesting excess unlabeled PR20 can compete with PR20-X for
proteasome binding sites, confirming that the PR20-X probe behaves similarly to
the unlabeled PR20 peptide. The patten of bands in lane 3 is similar to lane 1,
suggesting that the GR20 peptide cannot compete with PR20-X for proteasome
binding sites. This result agrees with the fact that the GR20 peptide is non-toxic
while the PR20 peptide is highly toxic.26 This result indicates the PR20 peptide can
bind to the proteasome subunits while the non-toxic GR20 peptide can not.
The three bands indentifed by the blotting experiment was anlyzed by the
Proteomics Core Facility at the Children’s Hospital of Philadelphia (CHOP)
Research Institute. Serveal protein candidates were identified based on the
molecular weight of the protein target (Table 2).51 The binding pattern is not
obvious according to the MS result. I hypothesize that all subunits that bind to the
PR20 peptide have a common motif, but further experiments with probe 4 is needed
to confirm the crosslinked protein identities and to explain the binding mechanism.
Table 2. Crosslinked Proteasome Proteins Candidates
molecular
UniProt
Band
weights
accession
Number candidate proteins
(Kda)
numbers
26S protease regulatory subunit 4
49
P62191
Band 1 26S
proteasome
non-ATPase
regulatory subunit 2
100
Q13200
26S
proteasome
non-ATPase
regulatory subunit 11
47
O00231
Band 2
Isoform 2 of 26S protease regulatory
subunit 8
45
P62195-2
Proteasome subunit alpha type-6
27
P60900
Proteasome subunit alpha type-3
28
P25788
Band 3 Proteasome subunit alpha type-5
26
P28066
Proteasome subunit beta type-7
30
Q99436
Proteasome subunit alpha type-7
28
O14818
Source: Adapted from Lan, M. The Role of the Proline-Arginine Dipeptide Repeat in
Amyotrophic Lateral Sclerosis. M.S. Dissertation, University of Pennsylvania, Philadelphia,
PA, USA, 2017.

Binding Competition of PRx Peptides with Different Lengths The final goal
of this project was to verify if the length of the PRx peptides determines the binding
activity and toxicity. In most previous studies, the PR20 peptide was used as the
model for toxic PRx.24,26 This gave rise to the question if the length of PRx peptides
can have effects in proteasome binding. To answer this question, I synthesized
two unlabeled versions of PRx peptide: (Pro-Arg)3 (7) and (Pro-Arg)5 (8) in this
project (Figure 16). A binding competition assay using 7 and 8 against the PR-X
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probe was performed to determine if peptide 7 and 8 can bind to the proteasome
and compete out the PR20-X probe (Kalb, R. Children's Hospital of Philadelphia,
PA, USA. Unpublished work, 2017).
Binding Competition Assay The binding competition assay was performed by
incubating the PR20-X probe, PR3 (7) and PR5 (8) peptides with proteasome
subunits. Then the mixture was crosslinked by UV irradiation followed by avidin
Blot (Figure 17). Lane 2 and lane 3 indicated the natural PR20 peptide could
compete out the PR20-X probe in proteasome binding. This serves as a control to
prove that the PR20-X probe and PR20 peptide have binding affinity. It can be
observed that the PR3 and the PR5 peptides do not compete with the PR20-X probe
to bind to the proteasome, as indicated by comparing lane 2 to lanes 6 and 7. This
suggested that PRx peptide binding to the proteasome is length dependent and
sufficiently cooperative; multiple PR3 or PR5 peptides cannot simply occupy the
binding site for PR20.

Figure 16. The Structure of PR3 Peptide 7 (top) and PR5 Peptide 8 (bottom)
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Figure 17. Binding Competition Assay by Streptavidin Blot. Lane 1 to 7 (left to right)
represents: ladder; PR20-X probe with proteasome; PR20-X peptide with
proteasome with extra PR20 peptide; GR20-X peptide with proteasome; identical to
lane 3 but with extra incubation time before UV irradiation; PR3 peptide and PR20X probe with proteasome; PR5 peptide and PR20-X probe with proteasome. All
samples were irradiated by UV at 365 nm for 30 min for crosslinking before the
streptavidin blot. The red boxes indicate the same bands as in Figure 15. (Kalb,
R. Children's Hospital of Philadelphia, PA, USA. Unpublished work, 2017)

Conclusion and Future Work
To summarize this study, our synthetic probes provided tools to study the
mechanism of ALS disease and histone function in vitro or in cells. In project 1, I
used SPPS to synthesize two 23-mer probes 1 and 2 to perform a crossslinking
experiment to identify the protein(s) that bind to an N-ac histone H4 peptide. In the
blotting experiment, some protein targets were found with binding preference to
the N-ac histone peptide. The next step would be to replicate these results and
use MS to identify the proteins. In project 2, I synthesized another set of probes,
including a 41-mer TAMRA fluorophore labeled PR20 peptide 3, and a 46-mer PR20
peptide with a photo-crosslinking warhead probe 4, a 6-mer PR3 peptide 7, and a
10-mer PR5 peptide 8. This set of probes were synthesized for the study of the
toxicity mechanism of PRx peptide. The preliminary in vitro result demonstrated
that the length of the PRx peptide plays in role in proteasome binding. The PRx
peptide binds to the proteasome with a defined pattern. The probes 3 and 6 will be
tested by the Kalb group.
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PRx Peptide Synthesis by Recombinant Protein Expression Peptides in the
30 to 40 amino acid range are usually too short for protein expression and are
generated by SPPS. In my syntheses of the PR20 peptide by SPPS, I found the
yields to be low due to the difficult removal of arginine Pbf sidechain protection
groups. To synthesize unconventional peptides like the PRx peptides, we would
like to use recombinant protein expression to synthesize the peptide. Purification
tags can facilitate protein expression and stabilize the peptide. Previously, the
Petersson laboratory successfully used an intein as a traceless purification tag to
express α-synuclein (140 amino acids) containing the unnatural amino acid pcyanophenylalanine at position 136 using orthogonal aminoacyl-tRNA
synthetase/tRNA pairs.52,53 I could use inteins and the Small Ubiquitin-like Modifier
(SUMO) proteins as a generalizable purification tag for medium size peptides that
are unsuitable for NCL, but too long for efficient SPPS.
We performed the preliminary experiment of PR20 peptide biosynthesis but the
result was unsuccessful. We transformed pET His6 Sumo TEV CPR20 plasmid
(Appendix A) into E. coli. BL21(DE3). Figure 18 shows the sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS Page) gel image of the SUMOCPR20 fusion protein expression and Ni column purification elution, stained with
Coomassie blue. Lane 1 and 2 is the cell lysate before and after transformation but
before Isopropyl β-D-1-thiogalactopyranoside (IPTG) induction, respectively. The
intense induction band near to the top of the gel at lane 2 suggests the fusion
protein can be readily induced by IPTG. However, the induction band could not be
observed in lane 3, which is from to harvested cell lysate and Ni column purification
elution, respectively. The loss of the induction band suggests that the target protein
was lost during the process of cell harvesting. We believe this is because the PR 20
fusion protein has a high arginine content. It was known that arginine has a high
binding affinity towards nucleic acids, so a protein with high arginine content is
likely to precipitate with other cellular components during cell harvesting process. 54
To overcome this problem, we need to find the cell lysing condition that prevents
Arginine from binding to nucleic acid. The addition of glycerol and high
concentration of potassium chloride into the cell lysing buffer can prevent the
interactions between arginine-rich peptides and nucleic acid (Skordalakes, E.
Wistar Institute, Philadelphia, PA. Personal communication, 2017.). This strategy
will be tested in the future.

Figure 18. SDS Page of His6-SUMO-CysPR20 Fusion Protein Expression and Ni
Column Purification.
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Chapter 2
Thioamide as a Proteolysis-resistant Modification
Introduction
Importance and Significance Peptide-based medicine has a wide range of
applications and huge value in marketing. The global annual sale of peptide-based
medicine was $14.1 billion in 2011 and was predicted to be $25.4 billion in 2018.55
One of the challenges to peptide-based medicine is that most naturally occurring
peptides are susceptible to proteolysis in plasma and have a very short half-life.
For example, the incretin hormone glucagon-like peptide-1 (GLP-1) has a half-life
of 1.5 to 5 minutes in plasma.56 The use of peptide cyclization, D- and β-amino
acids substitution can stabilize peptides in plasma.57,58 These three approaches
have had success in the past but they all change the structure or conformation of
the target molecules, which may lead to unpredictable effect on bioactivity. The
Petersson laboratory has recently showed that the single-atom substitution of the
thioamide can be introduced into protease substrates to stabilize peptides against
proteolysis. The thioamide modification can be used to stabilize peptides against
proteolysis in peptide-based medicine while introducing minimal perturbation to the
structure.
Thioamide Physical Properties The physical differences between the
thioamide bond and amide bond are summarized in Table 3. The thioamide bond
and amide bond are nearly isosteric, but the bond length of the thioamide bond is
longer. The thioamide bond is weaker and more polarizable compared to the amide
bond.59 The most significant differences between thioamide and amide are in the
hydrogen bond donor-acceptor properties. The sulfur atom in the thioamide is a
weaker hydrogen bond acceptor, but the adjacent N-H group is a stronger
hydrogen bond donor.60
Table 3. Thioamide Properties
X=O or S
Oxoamide
van der Waals radius (Å)
1.40
C=X bond length (Å)
1.24
C=X bond dissociation energy (kcal/mol)
170
N-H pKa
17
C-N rotational barrier (kcal/mol)
≈15-19
π to π* absorption (nm)
190
Oxidation potential (eV)
3.29

Thioamide
1.85
1.54-1.68
130
11-13
≈18-22
270
1.21

Source: Adapted from Petersson, E. J.; Goldberg, J. M.; Wissner, R. F. Phys. Chem.
Chem. Phys. 2014, 16, 6827–6837.

Thioamides as Fluorescence Quenchers Sulfur substitution shifts the amide
π to π* transition from 190 nm (oxo) to 270 nm (thio), giving it spectral overlap with
UV wavelength fluorophores that permits Förster resonance energy transfer
(FRET). In addition, there is a 2.1 eV change in the oxidation potential that makes
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thioamides able to act as electron donors in photo-induced electron transfer (PET)
reactions. These two properties allow the thioamide to be used as a quencher of
fluorophores including cyanophenylalanine (Cnf), acridonylalanine (Acd),
fluorescein (Fam), 7-methoxycoumarin (Mcm), tryptophan, and tyrosine.60,61
These quenching interactions can be used to monitor conformational changes in
proteins or cleavage by proteases, using doubly labeled peptides.62 The Petersson
laboratory previously developed a real-time proteolysis assay using fluorescence
labeled thioamide peptide.61 The probe was designed so that the Mcm
fluorescence was quenched by the thioamide. After the cleavage of the scissile
bond by the protease, the fluorescence was turned on and gave an increased
fluorescence signal that could be analyzed by a plate-reader, as shown in Figure
19. I used this approach to monitor the protease activity in this study.
General Proteases Properties Proteases, also referred as peptidases, or
proteinases are enzymes that catalyze the hydrolysis of peptide bonds. Protease
signaling pathways are vital to many biological processes and the activity of
proteases is highly regulated in the body.63 For this reason, many protease
inhibitors have been developed as therapeutics. Captopril is an angiotensinconverting enzyme (ACE) protease inhibitor for hypertension treatment;63 Ritonavir
is a (human immunodeficiency virus) HIV protease inhibitor for (acquired
immunodeficiency syndrome) AIDS treatment;63 Sivelestat is a neutrophil elastase
inhibitor for acute respiratory failure treatment.63
The substrates of protease follow a special nomenclature: residues in the Nterminal direction from the cleaved bond are designated P1, P2, P3, P4 etc.; the
residues in C-terminal direction are designated P1', P2', P3', P4'. etc. 64 Based on
the site of cleavage, proteases can be divided in to endopeptidase and
exopeptidase. Endopeptidase cleave peptide bonds of at non-terminal amino acids
while exopeptidase cleave peptide bonds of terminal amino acids. Based on the
mechanism of catalysis, proteases in mammals can be classified into five classes:
aspartic, cysteine, serine, threonine, and metalloproteases proteases.65 Among
these classes, serine protease class is the best studied class, which uses the
classical Ser/His/Asp catalytic triad mechanism, where the serine residue is used
as the nucleophile.66 Since proteases degrade peptide-based medicine in vivo, it
is critical to understand the effect of thioamide incorporation with different classes
of proteases.
Previous Thiopeptide Protease-Resistant Studies Since hydrogen bonds
play critical roles in biological activities, the altered hydrogen bond properties can
change the potency and stability of the peptide. The changes of properties depend
on the site of incorporation. A thioamide at position 2 of the Leu-enkephalin (LeuEnk) peptide increased the potency, but a thioamide at position 1 or 3 decreased
the potency, as shown in Figure 20.67 Certain thioamide peptides has been shown
to be resistant against carboxypeptidase A,68–71 HIV-1 proteases,72 membrane
dipeptidase,73 papain,74 trypsin,75 leucine aminopeptidase,76 and prolyl
oligopeptidase.77 Some studies have also previously evaluated the effectiveness
of thio-peptide therapeutics in vivo. Zhang and coworkers78 showed that polybiaMPI thio-peptides has increased the half-life and anticancer activity. Zacharie and
coworkers79 reported thioamide Imreg peptides have slightly improved in vivo
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immune-stimulant effect and serum half-life. In all studies, the activity and
proteolysis stability of thioamide largely depends on the position of thioamide
incorporation.

Figure 19. Mechanism of Singly Labeled Fluorescence Probe.61

Figure 20. Chemical Structure of Leu-enkephalin Peptide.67
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Purpose For applications in peptide therapeutics, the positioning of the
thioamide must be disruptive to interactions with the protease, but not with the
peptide receptor. The Petersson laboratory has demonstrated thioamide peptide
can stabilize GLP-1 without disrupting activity in cell based assays.80 In separate
work, the Petersson laboratory has demonstrated that thioamide quenchers can
be used in fluorescent peptide sensors to probe to protease activity.61 In the case
of protease sensors, one wishes the thioamide to be as close as possible to the
scissile bond without altering kcat or KM compared to the parent peptide. To fulfill
both requirements for thioamide, it is important to gain a predictive understanding
of which thioamide positions are disruptive for a given protease. To gain a better
understanding of the positional effects of thioamide, I synthesized a set of probes
with thioamide at each peptide bond positions and measure the rates of proteolysis.
Experimental Design The Petersson laboratory previously demonstrated that
thioamides can be used as fluorescence quenchers in protease activity sensors
using the probe shown in Figure 19. This sensor can monitor the activity of
protease, but cannot be used to study the positional effect of thioamide due to
limitations to the possible positions of thioamide incorporation. The singly labeled
probe cannot provide kinetic information for the oxo-peptide control. To overcome
these two problems, a doubly labeled peptide sensor was designed with identical
fluorophores at each end, as shown in Figure 21 (fluorophores highlighted in blue).
7-methoxycoumarin (Mcm) was chosen as the fluorophore for the sensor since
Mcm can be quenched by both thioamide and by intramolecular self-quenching.
This probe design can monitor the rate of proteolysis with thioamide incorporated
at any peptide bond position. The synthesis and proteolysis assays followed the
previous established methods.61

Figure 21. Proposed Template of Doubly Labeled Thioamide Proteolysis Sensor
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Materials and Methods
General Information Fmoc-β-(7-methoxycoumarin-4-yl)-Ala-OH (µ) was
purchased from Bachem (Torrance, CA, USA). Fmoc-Lys(biotinyl)-OH was
purchased from TCI America (Portland, OR, USA). 2-(1H-benzotriazol-1-yl)1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU), 2-Chlorotrityl chloride
resin (100-200 mesh, 1% DVB), Fmoc-Ala-OH, Fmoc-Lys(Boc)-OH, Fmoc-PheOH were purchased from Novabiochem (currently EMD Millipore; Billerica, MA,
USA). Piperidine was purchased from American Bioanalytical (Natick, MA, USA).
Sigmacote®, N,N-diisopropylethylamine (DIPEA), 1,8-Diazabicyclo[5.4.0]undec7-ene (DBU) and Trifluoroacetic acid (TFA) were purchased from Sigma-Aldrich
(St. Louis, MO, USA). Glass peptide synthesis reaction vessels (RVs) were treated
with Sigmacote® prior to use. Triisopropylsilane (TIPS) was purchased from Santa
Cruz Biotechnology (Dallas, TX, USA). Chymotrypsin (lyophilized powder; from
Bovine Pancreases) was purchased from MP Biomedicals (Santa Ana, CA, USA).
Nα-Fmoc-L-Alanine-2-amino-5-nitroanilide and Nα-Fmoc-L- Phenylalanine-2amino-5-nitroanilide were synthesized by former lab member Yanxin Wang. All
other reagents including solvents were purchased from Fisher Scientific (Hampton,
NH, USA) unless specified otherwise.
Instruments Crude peptides were purified with a Varian ProStar HighPerformance Liquid Chromatography (HPLC) instrument outfitted with a diode
array detector (currently Agilent Technologies) using aqueous A (H2O + 0.1% TFA)
and organic B (CH3CN + 0.1% TFA) phases. Purification testing was performed in
an Agilent 1100 Series HPLC with a 4.6nm Phenomenex Luna C8 (2) column. UV
absorbance spectra were obtained with a Hewlett-Packard 8452A diode array
spectrophotometer (currently Agilent Technologies; Santa Clara, CA, USA).
Matrix-assisted laser desorption ionization (MALDI) mass spectrometry (MS) data
were collected with a Bruker Ultraflex III MALDI-TOF-TOF mass spectrometer
(Billerica, MA, USA). Fluorescence spectra were collected with a Tecan M1000
plate reader (San Jose, CA, USA)
Peptide Synthesis The synthesis of thioamide peptide was performed following
a published method.81 For amino acids other than thioamide-containing amino
acids, a standard synthetic method identical to Chapter 1 was performed. To
couple the thioamide, 2 equiv. of pre-activated precursors was dissolved in 2 ml of
dry dichloromethane (DCM) and then added to the RV. 2 equiv. of DIPEA was
added to the RV and stirred for 30 min. The RV was drained, then another 2 equiv.
of pre-activated precursors in dry DCM was added to the RV with 2 equiv. of DIPEA,
stirred for 30min and then drained. The Fmoc deprotection for thioamide amino
acids was performed by treatment with 2% 1,8-Diazabicyclo[5.4.0]undec-7-ene
(DBU) in DMF for 2 min, for three times.
After the last synthesis step, the peptide was cleaved from the resin by
treatment of 2 ml of cleavage cocktail for 30 minutes with stirring (30% TFA, 2.5%
TIPS, 2.5% water, 65% DCM). The TFA from crude peptide was removed by
adding 2 ml of ACN and evaporated in a rotary evaporator twice. The crude peptide
was then purified by HPLC and freeze dried. MALDI-TOF was used to confirm the
identity of the peptide and purity was verified by an analytical HPLC.
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Steady State Protease Assays To obtain kinetic data of peptide hydrolysis,
the peptide was dissolved in 100 mM Tris-HCl buffer (pH 7.8) and standardized
the concentration by measuring the UV absorbance at 325 nm to 5.0 µM. The
peptides were added to a 96-well plate (Greiner Bio-One, 675096) and incubated
in the Tecan plate reader with shaking between each measurement at 25 °C. The
fluorescence was monitored as a function of time using excitation wavelength of
325 nm and emission wavelength of 390 nm. Chymotrypsin enzyme was dissolved
in 1 mM HCl, 10mM CaCl2, to a final concentration of 2.5 mg/ ml. The hydrolysis
was initiated by adding 4 µl of the enzyme to each 46 µl peptide, making a final
enzyme concentration of 0.2 mg/ml. For control groups, 4 µl of 1 mM HCl, 10mM
CaCl2 was added to the peptide. Each hydrolysis trail was performed in triplicates
and control in duplicates. The result of the three trials was averaged and fitted to
the one phase decay exponential function using GraphPad Prism to calculate the
half-life.

Results and Discussion
Peptide Characterization To monitor the positional effects of thioamides on
chymotrypsin proteolysis, doubly Mcm-labeled peptides with a thioamide at each
peptide position from P4 to P3’ were synthesized (10-16). The corresponding oxopeptide was also synthesized as the control (9). Peptide 9, 13-15 were synthesized
by Chunxiao Liu, Peptide 15 was synthesized by Xing Chen. I synthesized peptide
10-12. All peptides synthesized were characterized by MALDI-MS, expected
[M+H]+ ions were observed as shown in Table 4, which μ refers to Mcm derivative
β-(7-methoxycoumarin-4-yl)-Ala and superscript S refers to position of thioamide.
Table 4. Characterization of Thioamide Peptides
Molecule
Sequence
Calculated (m/z)
Observed (m/z)
9
10

μKAAFAAAμ
μKSAAFAAAμ

1139
1155

1139
1155

11

μKASAFAAAμ

1155

1155

12

μKAASFAAAμ

1155

1155

13

μKAAFSAAAμ

1155

1155

14

μKAAFASAAμ

1155

1155

15

μKAAFAASAμ

1155

1155

16

μKAAFAAASμ

1155

1155

Enzyme Activity Assays Positional screening of thio-peptides hydrolysis from
P4 to P3’ positions was performed using chymotrypsin. Chymotrypsin hydrolysis
was carried out with 45 µl of the 5µM peptide concentration in 100 mM HCl, pH
7.8, at room temperature in the presence or absence of 0.2 mg/ml chymotrypsin.
Figure 22 shows the fluorescence traces of peptide hydrolysis. The fluorescence
intensity of peptides without protease (orange traces) was approximately 60%
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lower than the intensity after hydrolysis (red traces), indicating the doubly labeled
thioamide peptides was quenched by approximately 60%. The fluorescence
intensities of peptides without protease (orange traces) remained constant over
the course of the experiment, demonstrating that the probes were stable during
the experiment. Upon addition of the protease, the fluorescence signals increased
exponentially over time and reached plateaus (red traces). This gain of
fluorescence corresponded to the cleavage of the peptides. For peptides showing
proteolysis inhibition, the growth of fluorescence intensities was slower and the
traces were almost linear. The half-lives were calculated by fitting curves to a
single exponential function using GraphPad Prism, and are shown in Table 5. The
oxo-peptide 5 could not be fully dissolved in the buffer, hence the hydrolysis
experiment was not performed. Data for P4 to P1 positions were obtained from
former lab member Xing Chen.80 The calculated half-lives showed that for
chymotrypsin, a thioamide at the P1 or P2 position can greatly inhibit proteolysis.

Figure 22. Representative Results for Chymotrypsin Proteolysis.
Top (left to right): thioamide incorporated to P3, P2, P1 positions, respectively. Bottom
(left to right): thioamide incorporated to P1’, P2’, P3’ positions, respectively. Red traces:
Hydrolysis with chymotrypsin; Orange traces: Peptides without chymotrypsin. Three
independent trials for each protease are shown as open circles, thin lines, and thick lines.
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Table 5. Thioamide Positional Effects on Chymotrypsin Activity
Molecule
Thioamide
Sequence
Chymotrypsin t 1/2 (min)
Position
9
Control
μKAAFAAAμ
not determined
S
10
P4
μK AAFAAAμ
0.37±0.01
S
11
P3
μKA AFAAAμ
1.19±0.02
S
12
P2
μKAA FAAAμ
>40
S
13
P1
μKAAF AAAμ
>40
S
14
P1'
μKAAFA AAμ
0.19±0.06
S
15
P2'
μKAAFAA Aμ
0.25±0.05
S
16
P3'
μKAAFAAA μ
0.32±0.06

Figure 23. Nucleophilic Attack Step of Serine Protease.83
Sources: Adapted with permission from Ekici, O. D.; Paetzel, M.; Dalbey, R. E.
Unconventional Serine Proteases: Variations on the Catalytic Ser/His/Asp Triad
Configuration. Protein Sci. 2008, 17 (12), 2023–2037.

The protease resistance at the P1 position can be explained by the catalytic
mechanism. Figure 23 shows the nucleophilic attack step of the serine protease,
were the serine sidechain serve as a nucleophile and attacks the peptide bond.
His 57 is pulling a proton from Ser 195 (labeled as 2 in Figure 23 and 24), the
protonated Ser 195 can act as a nucleophile to attack the amide bond (labeled as
1). A close examination of the crystal structure of α-chymotrypsin bound with its
inhibitor shows the P1 position peptide bond is closely interacting with protein
backbone at Gly 193, Asp 194 and Ser 195 positions, labeled as 3, 4, and 5,
respectively in Figure 24.82 Since the bond length of thioamide is longer than
oxoamide and sulfur atom is larger than oxygen, the substrate binding can be
sterically prohibited and inhibit proteolysis. In addition, the sulfur atom is a weaker
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hydrogen bond acceptor, the reaction intermediates are destabilized in thioamide
bonds, making the hydrolysis unfavorable. The inhibition mechanism on the P2
position is not obvious by inspecting the crystal structure. It is possible that the
thioamide bond has a higher rotation energy barrier than the amide bond, and the
substrate with thioamide at the P2 position cannot adapt the correct confirmation.
For FRET experiment applications, thioamide has the advantage of having a
smaller size over other FRET quenchers. The typical fluorophores for FRET
experiments are larger than the size of an amino acid while the thioamide is only
a single atom substitution. The introduction of a large fluorophore molecule to the
protein may perturb the structure of the protein and makes the measurements
unreliable. In contrast, the isosteric thioamide is minimally-perturbing. For peptidebased medicine applications, thioamides can prevent the drug from protease
degradation, if incorporated at the right position. However, since the thioamide
bond is weaker than the oxoamide bond, thioamide peptide drugs may potentially
have a shorter shelf life.

Figure 24. Crystal Structure of Chymotrypsin with Inhibitor from Insect Locusta
migratoria (PMP-C).82
Sources: Adapted from Roussel, A.; Mathieu, M.; Dobbs, A.; Luu, B.; Cambillau, C.;
Kellenberger, C. Complexation of Two Proteic Insect Inhibitors to the Active Site of
Chymotrypsin Suggests Decoupled Roles for Binding and Selectivity. J. Biol. Chem. 2001,
276 (42), 38893–38898. (PDB ID: 1GL1)
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Conclusion and Future Work
To evaluate the effect of thioamides to the proteolysis process, collaborators
and I synthesized one set of hydrolysis sensors with thioamide substitution from
P4 to P3’ positions, and performed hydrolysis studies using chymotrypsin. The
result revealed that thioamide at the P1 or P2 positions can greatly inhibit
chymotrypsin hydrolysis. This initial result of protease inhibition is useful for
peptide based drug design and other hydrolysis probe design. If peptides of
therapeutic interest are known to be cleaved by chymotrypsin-like enzymes, they
could be modified with thioamides at the P2 or P1 positions for stabilization.
Several future experiments are suggested by our results. Obtaining the
Michaelis–Menten kinetics parameters of thioamide probes can provide
information about the mechanism of thioamide proteolysis resistance. MichaelisMenten kinetics can be obtained by performing the photolysis experiment at
different concentrations of the substrates and fit into a Michaelis–Menten model.84
Enzymatic Thioamide Synthetic Route Although we successfully coupled
thioamides into peptides, the yields were only approximately 10-25% of the
corresponding oxo-peptide yield. To make thioamide peptides a more generallyaccessible tool, it is important to optimize the yield of the synthesis. Using an
enzymatic reaction to introduce a backbone thioamide is a possible way to
increase yield. Dunbar and Mitchell85 reported an ATP-dependent
cyclodehydratase that can cyclize a peptide on Cys, Ser, and Thr residues, forming
a heterocyclic azoline structure (Figure 25). This azoline intermediate can be
released with KHS, forming a backbone thioamide. This reaction can introduce
backbone thioamide modifications to an expressed protein at specific locations.
Currently, such protein can only be made by synthesizing peptide fragments and
then ligating the fragments. This process is labor intensive and involves multiple
purification steps. Incorporating thioamide to an expressed protein with enzyme is
far more efficient.

Figure 25. Scheme of Thioamide Formation by Cyclodehyratase.85
Sources: Adapted with permission from Dunbar, K. L.; Mitchell, D. A. Insights into the
Mechanism of Peptide Cyclodehydrations Achieved through the Chemoenzymatic
Generation of Amide Derivatives. J. Am. Chem. Soc. 2013, 135 (23), 8692–8701.
Copyright 2013 American Chemical Society.
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